US › Healthcare

Black Diamond Therapeutics Inc (BDTX)

US · Healthcare · Biotechnology

$1.78+2.59%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-9.0M
Profit YoY
-116.0%
EPS
$-0.16
EPS estimate
$-0.21

EPS came in at -0.16 against a street estimate of -0.21 — a beat of 23.8%.

Key statistics

Market cap
$96.8M
Forward P/E
8.3
P/B
0.93
Book value
$1.82
EPS (TTM)
$-0.77
52-week high
$4.94
52-week low
$1.60
50-day MA
$1.95
200-day MA
$2.64
Beta
3.25

Analyst view

Analysts rate Black Diamond Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $9.86.

Shareholding

Insiders
0.65%
Institutions
67.33%

Largest institutional holders

FundStake
T. Rowe Price Investment Management,Inc.18.43%
NEA Management Company, LLC7.76%
Acadian Asset Management LLC4.10%
Vanguard Capital Management, LLC3.23%
Renaissance Technologies Corp2.87%
Dimensional Fund Advisors, Inc.2.27%
BlackRock Inc1.93%
Connor Clark & Lunn Inv Mgmt Ltd1.85%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Black Diamond Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.